Cargando…

Correction to: Current status of ctDNA in precision oncology for hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Li, Yan, Zheng, Yuanyuan, Wu, Liwei, Li, Jingjing, Ji, Jie, Yu, Qiang, Dai, Weiqi, Feng, Jiao, Wu, Jianye, Guo, Chuanyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276488/ https://www.ncbi.nlm.nih.gov/pubmed/34256827 http://dx.doi.org/10.1186/s13046-021-02032-3

Ejemplares similares

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
por: Feng, Jiao, et al.
Publicado: (2020)

Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
por: Yu, Qiang, et al.
Publicado: (2020)

Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway
por: Yu, Qiang, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Next-generation ctDNA-driven clinical trials in precision immuno-oncology
por: Aggarwal, Charu, et al.
Publicado: (2023)

Cellular based immunotherapy for primary liver cancer
por: Zheng, Yuanyuan, et al.
Publicado: (2021)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023)

Fenofibrate Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice: Involvements of Apoptosis, Autophagy, and PPAR-α Activation
por: Zhang, Jie, et al.
Publicado: (2021)

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
por: Feng, Jiao, et al.
Publicado: (2020)

PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
por: Feng, Jiao, et al.
Publicado: (2019)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
por: Liu, Tong, et al.
Publicado: (2020)

Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway
por: Wu, Liwei, et al.
Publicado: (2019)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-β1/Smad3 and p38/PPARα Pathways
por: Ji, Jie, et al.
Publicado: (2021)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
por: Kopystecka, Agnieszka, et al.
Publicado: (2023)

Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction
por: Zheng, Yuanyuan, et al.
Publicado: (2023)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing
por: Li, Qiaolian, et al.
Publicado: (2021)

TGF‐β/Smad and JAK/STAT pathways are involved in the anti‐fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis
por: Xu, Shizan, et al.
Publicado: (2020)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice
por: Li, Jingjing, et al.
Publicado: (2017)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer
por: Yang, Yang, et al.
Publicado: (2022)

PET/CT in Oncology: Current Status and Perspectives
por: Czernin, Johannes, et al.
Publicado: (2013)

ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma
por: Biglari, Negin, et al.
Publicado: (2023)

15-Deoxy-∆-(12,14)-Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR-γ: Function and Mechanism
por: Li, Jingjing, et al.
Publicado: (2019)

Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent
por: Li, Jingjing, et al.
Publicado: (2020)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death
por: Li, Sainan, et al.
Publicado: (2017)

Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis
por: Feng, Jiao, et al.
Publicado: (2019)

Alleviation of Hepatic Ischemia Reperfusion Injury by Oleanolic Acid Pretreating via Reducing HMGB1 Release and Inhibiting Apoptosis and Autophagy
por: Wang, Wenwen, et al.
Publicado: (2019)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2idgj6om00tsqjo3hnbmdgdol